Authors

• Eric Gauthier
• Meghan Karuturi (ORCID: https://orcid.org/0000-0001-8795-3901)
• Yan Ji (ORCID: https://orcid.org/0000-0001-9569-0574)
• John Migas
• Timothy Pluard (ORCID: https://orcid.org/0000-0002-3640-3077)
• Joanne L. Blum (ORCID: https://orcid.org/0000-0002-7951-6645)
• Monica Z Montelongo
• Erin Jepsen
• Shailendra Lakhanpal
• Yao Wang
• Joseph C. Cappelleri (ORCID: https://orcid.org/0000-0001-9586-0748)
• Gabrielle Betty Rocque (ORCID: https://orcid.org/0000-0003-4188-9785)
• Connie Chen
• Debu Tripathy (ORCID: https://orcid.org/0000-0002-5711-2404)

Institutions

• St. Vincent's Birmingham (US)
• The University of Texas MD Anderson Cancer Center (US)
• Pfizer (United States) (US)
• Texas Oncology (US)
• Novant Health (US)
• University of Alabama at Birmingham (US)
• St. Vincent's Birmingham (US)
• Saint Vincent's Catholic Medical Center (US)
• Imperial Consultants (GB)
• Saint Luke's Hospital (US)
• Mid Illinois Hematology and Oncology Associates (US)
• HealthPartners (US)

Publication Details

Journal

The Oncologist

Published

2025-09-12

DOI

https://doi.org/10.1093/oncolo/oyaf281

Primary Topic

Advanced Breast Cancer Therapies

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Pfizer
• AstraZeneca
• Gilead Sciences
• Jazz Pharmaceuticals
• Genentech
• Daiichi Sankyo Europe